These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 25952648)

  • 21. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
    King JW; Nathan PD
    Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma.
    Steeb T; Wessely A; Ruzicka T; Heppt MV; Berking C
    Eur J Cancer; 2018 Nov; 103():41-51. PubMed ID: 30205280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.
    von Euw E; Atefi M; Attar N; Chu C; Zachariah S; Burgess BL; Mok S; Ng C; Wong DJ; Chmielowski B; Lichter DI; Koya RC; McCannel TA; Izmailova E; Ribas A
    Mol Cancer; 2012 Apr; 11():22. PubMed ID: 22515704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives.
    Komatsubara KM; Manson DK; Carvajal RD
    Future Oncol; 2016 Jun; 12(11):1331-44. PubMed ID: 27044592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
    Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
    BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study.
    Mallikarjuna K; Pushparaj V; Biswas J; Krishnakumar S
    Curr Eye Res; 2007 Mar; 32(3):281-90. PubMed ID: 17453948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
    Liu L; Mayes PA; Eastman S; Shi H; Yadavilli S; Zhang T; Yang J; Seestaller-Wehr L; Zhang SY; Hopson C; Tsvetkov L; Jing J; Zhang S; Smothers J; Hoos A
    Clin Cancer Res; 2015 Apr; 21(7):1639-51. PubMed ID: 25589619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natural withanolide withaferin A induces apoptosis in uveal melanoma cells by suppression of Akt and c-MET activation.
    Samadi AK; Cohen SM; Mukerji R; Chaguturu V; Zhang X; Timmermann BN; Cohen MS; Person EA
    Tumour Biol; 2012 Aug; 33(4):1179-89. PubMed ID: 22477711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma.
    Mergener S; Siveke JT; Peña-Llopis S
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trametinib in metastatic melanoma.
    Chopra N; Nathan PD
    Expert Rev Anticancer Ther; 2015; 15(7):749-60. PubMed ID: 26107021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma.
    Verykiou S; Alexander M; Edwards N; Plummer R; Chaudhry B; Lovat PE; Hill DS
    Br J Dermatol; 2019 Feb; 180(2):346-356. PubMed ID: 30339727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models.
    Meetze K; Vincent S; Tyler S; Mazsa EK; Delpero AR; Bottega S; McIntosh D; Nicoletti R; Winston WM; Weiler S; Feng B; Gyuris J; Weng Z
    Clin Cancer Res; 2015 Mar; 21(5):1106-14. PubMed ID: 25542901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death.
    Ambrosini G; Musi E; Ho AL; de Stanchina E; Schwartz GK
    Mol Cancer Ther; 2013 May; 12(5):768-76. PubMed ID: 23443802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro.
    Zalesna I; Osrodek M; Hartman ML; Rozanski M; Sztiller-Sikorska M; Niewinna K; Nejc D; Czyz M
    PLoS One; 2017; 12(8):e0183498. PubMed ID: 28829835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications.
    Economou MA; All-Ericsson C; Bykov V; Girnita L; Bartolazzi A; Larsson O; Seregard S
    Acta Ophthalmol; 2008 Nov; 86 Thesis 4():20-5. PubMed ID: 19032678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies.
    Fattore L; Marra E; Pisanu ME; Noto A; de Vitis C; Belleudi F; Aurisicchio L; Mancini R; Torrisi MR; Ascierto PA; Ciliberto G
    J Transl Med; 2013 Jul; 11():180. PubMed ID: 23890105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential.
    Wu X; Zhou J; Rogers AM; Jänne PA; Benedettini E; Loda M; Hodi FS
    Melanoma Res; 2012 Apr; 22(2):123-32. PubMed ID: 22343486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression.
    Gangemi R; Mirisola V; Barisione G; Fabbi M; Brizzolara A; Lanza F; Mosci C; Salvi S; Gualco M; Truini M; Angelini G; Boccardo S; Cilli M; Airoldi I; Queirolo P; Jager MJ; Daga A; Pfeffer U; Ferrini S
    PLoS One; 2012; 7(1):e29989. PubMed ID: 22267972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.